BE study Design for Ri­va­rox­aban 20 mg [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-04 13:33 (512 d 02:36 ago) – Posting: # 23103
Views: 1,893


The Design for Rivaroxaban 20 mg BE Study stated by US-FDA is as follows:

Single-dose, two-treatment, two-sequence, four-period, fully replicate crossover

Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?

Thank You!

Edit: Category changed; see also this post #1. Guidance linked. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,811 posts in 4,783 threads, 1,642 registered users;
38 visitors (0 registered, 38 guests [including 20 identified bots]).
Forum time: 15:09 CET (Europe/Vienna)

The first time I was in a statistics course,
I was there to teach it.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz